Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

Elizabeth A. Harrington, David Bebbington, Jeffrey R. Moore et al. · Nature Medicine · 2004 · 948 citations · Full text

Selective Small-molecule Inhibitor, Signal Transduction, Signaling Pathway +11

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Francis J. Giles, Jörge E. Cortes, Dan Jones et al. · Blood · 2006 · 361 citations · Full text

The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function

Farid Gizatullin, Yao Yao, Victor Kung et al. · Cancer Research · 2006 · 177 citations · Full text

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

Joan H. Schiller, Timothy Larson, S.-H.I. Ou et al. · Journal of Clinical Oncology · 2009 · 173 citations · Full text